A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability

Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, fast-dissolving tablet Zydis technology.

The new drug delivery platform is a freeze-dried, oral solid dosage form that rapidly disperses in the mouth (not requiring water) which holds the potential for better absorption, a more efficient delivery, rapid onset of effects, a better patient experience and compliance.

See also: Psychedelics Companies Seek Innovative Methods To Deliver Assisted Therapies, This One Stands Out

Faster onset of effects could lead to shortening therapy sessions and, through pre-gastric absorption and bypassing of the first-pass metabolism, enhanced pharmacokinetics (PK.)

Awakn’s CSO Shaun McNulty stated that Catalent is “a world leader” in formulation and that their Zydis ODT technology is “the gold standard” for rapid, safe and consistent delivery of drugs to patients. 

See also: EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC

“This study has the potential to demonstrate that Zydis ODT technology can provide an ideal MDMA formulation option both for patients and for health care providers,” McNulty concluded.

Photo: Benzinga edit with photo by Bacsica, aiyoshi597, Gisele Yashar and August_0802 on Shutterstock.